Abstract: New N-substituted cyclic amines of formula: ##STR1## wherein: X, R.sub.1, R.sub.2 and R are as defined in the description, their optical and geometric isomers and physiologically tolerable salts thereof. The compounds of the invention are powerful PDE4 inhibitors and can be used therapeutically.

Abstract: A compound of general formula (I): ##STR1## in which: R.sub.1 represents alkyl,X represents oxygen, --CHR'-- or --CR'.dbd.,R' is chosen from hydrogen and alkyl,R.sub.2 represents optionally substituted alkyl as is defined in the description, cycloalkyl or polycycloalkyl as are defined in the description,R.sub.3 represents hydrogen or hydroxyl,Alk represents alkylene, andY is as defined in the description,and medicinal products containing the same are useful as PDE IV inhibitors.

Abstract: A compound of formula (I): ##STR1## in which: R.sub.1 represents an indolyl, naphthyl, tetrahydronaphthyl, thienyl, phenyl, optionally substituted, or (C.sub.3 -C.sub.7)cycloalkyl group,n represents an integer such that 1.ltoreq.n.ltoreq.8,m represents an integer such that 1.ltoreq.m.ltoreq.4,R.sub.2 represents an unsubstituted or substituted benzyl group, an unsubstituted or substituted phenyl group or a linear or branched (C.sub.1 -C.sub.6)alkyl group, its enantiomers, diastereoisomers and epimers as well as its addition salts with a pharmaceutically acceptable acid or base, and medicinal products containing the same are useful as substance P antagonists.

Abstract: The invention provides new compounds pertaining to the class of:aryl methoxy phenyl alkyl heterocyclic spiro compounds, enantiomers, diastereoisomers and physiologically-tolerable salts thereof.For example:8-{2-?3-quinol-2-yl methoxy)phenyl!ethyl}-3,8-diaza-1-oxa-2-oxo spiro?4,5!decane is described.Medicinal products containing the same are useful in the treatment of any pathology involving modifications of leukotriene metabolism.

Abstract: The invention relates to the compounds of formula (I): ##STR1## in which: R.sub.1 represents alkyl, phenyl, naphthyl, pyridyl or thienyl group, each phenyl, naphthyl, pyridyl or thienyl optionally being substituted,R.sub.2 represents a hydrogen atom or a substituted or unsubstituted alkyl, substituted or unsubstituted phenyl, cycloalkyl, piperidino or substituted or unsubstituted amino group,X represents CO or SO.sub.2,R.sub.3 represents hydrogen or alkyl,R.sub.4 represents alkyl, substituted or unsubstituted phenyl or trihalomethyl, or else R.sub.3 and R.sub.4 form, together with the carbon atoms which carry them, cyclo(C.sub.3 -C.sub.7)alkenyl,A represents phenyl, naphthyl or pyridyl ring, each phenyl, naphthyl or pyridyl ring optionally being substituted,their isomers, the corresponding quaternary ammonium salts of the piperidine and their addition salts with a pharmaceutically acceptable acid, an medicinal products containing the same are useful as antagonists of NK.sub.1 receptors.

Abstract: Disclosed herein are new diosmetin compounds of formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined in the description.The said compounds are useful in the treatment of chronic venous insufficiency.

Abstract: Compounds of formula (I): ##STR1## in which: R.sub.1 represents alkyl or (C.sub.3 -C.sub.7) cycloalkylR.sub.2 represents alkyl, or (C.sub.3 -C.sub.7) cycloalkyl,R.sub.3 represents hydrogen or alkyl,R.sub.4 represents halogen or alkyl or alkoxy,R.sub.5 represents alkyl,X and Y, which are different, represent CO or SO.sub.2,n represents 1, 2 or 3,p represents 0 or 1,Z represents sulfur or oxygen,A represents any one of the following groups: ##STR2## in which: A.sub.1 represents, with the nitrogen and carbon atoms to which it is attached, a mono- or bicyclic heterocycle,.cndot. or, ##STR3## in which: R.sub.6 represents hydrogen, alkyl or cycloalkyl or 2-indanyl,R.sub.7 represents hydrogen or alkyl,which compounds of formula (I) comprise thereof corresponding hydrates of the ketone function COCF.sub.3,the enantiomers, diastereoisomers and epimers thereof and the addition salts thereof with a pharmaceutically acceptable base and medical products containing the same are useful as HLE inhibitor.

Abstract: Compounds of formula (I): ##STR1## wherein: R.sub.1 represents an unsubstituted or substituted alkyl,R.sub.2 represents an unsubstituted or substituted alkyl,A represents, with the nitrogen and carbon atoms to which it is attached, a nitrogenous mono- or polycyclic structure, andB represent any one of the radicals a through j as defined in the description, and medicaments containing the same, are useful as human leucocyte elastase inhibitors.

Abstract: A compound of formula (I): ##STR1## in which: R represents naphthyl, 5,6,7,8-tetrahydronaphthyl, 1,2,3,4-tetrahydronaphthyl, thienyl, optionally substituted phenyl or (C.sub.3 -C.sub.7)cycloalkyl,n represents an integer such that 1.ltoreq.n.ltoreq.8, their enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid or base and medicinal products containing the same are useful as antagonists of substance P.

Abstract: Compound of formula:G-Arg-Pro-Hyp-Gly-Thia-Ser-Tic-Oic-Arg-OHwhere G, Arg, Pro, Hyp, Gly, Thia, Ser, Tic and Oic are defined in the description.Medicinal products.